Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monogram Orthopaedics Inc ( (MGRM) ) has issued an announcement.
Monogram Orthopaedics Inc, an AI-driven orthopedic robotics company, has been acquired by Zimmer Biomet, a global leader in medical technology. The merger, completed on October 7, 2025, positions Zimmer Biomet to offer the first fully autonomous robotic solution for orthopedic procedures, enhancing its existing portfolio of robotic and navigation technologies. As part of the merger, Monogram’s shares have been delisted from NASDAQ, and its technologies are expected to be integrated into Zimmer Biomet’s offerings, potentially impacting the company’s innovation pipeline and growth strategy.
The most recent analyst rating on (MGRM) stock is a Buy with a $10.80 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Average Trading Volume: 409,693
Technical Sentiment Signal: Buy
For detailed information about MGRM stock, go to TipRanks’ Stock Analysis page.